HRQoL outcomes with luspatercept vs epoetin alfa in transfusion-dependent LR-MDS: COMMANDS analysis скачать в хорошем качестве

HRQoL outcomes with luspatercept vs epoetin alfa in transfusion-dependent LR-MDS: COMMANDS analysis

Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, comments on the results of an analysis of data from the Phase III COMMANDS study (NCT03682536), which compared luspatercept and epoetin alfa for treating transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS). Dr Oliva highlights that luspatercept demonstrated a sustained benefit over epoetin alfa on shortening the time to achieving a meaningful improvement in health-related quality of life (HRQoL) or delaying the time to experience a significant HRQoL deterioration. The findings further confirms that luspatercept is an an appropriate first-line treatment for patients with transfusion-dependent LR-MDS. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.